Curable sexually transmitted infections among women with HIV in sub-Saharan Africa
Jana Jarolimova(Harvard University), Caitlin M. Dugdale(Brown University), Robert A. Parker(Harvard University), Khallela Barracks(Barnard College), Linda‐Gail Bekker(Desmond Tutu HIV Foundation), Maryam Shahmanesh(Africa Health Research Institute), Megan Rose Curtis(Washington University in St. Louis), Ingrid V. Bassett(Apple (Israel)), Laura Platt(Portland State University), Andrea Ciaranello(Harvard University), Lisa Philpotts(Massachusetts General Hospital), Chelsea Morroni(MRC Centre for Reproductive Health), Aamirah Mussa(Botswana Harvard AIDS Institute Partnership)
UCL Discovery (University College London)
April 1, 2022
Cited by 32
Related Papers
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
|Nature|2022|623
Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study
|The Lancet Infectious Diseases|2011|385
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
|Vaccine|2011|308
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
|New England Journal of Medicine|2021|231
Microbial Composition Predicts Genital Tract Inflammation and Persistent Bacterial Vaginosis in South African Adolescent Females
|Infection and Immunity|2017|179